Antinuclear Antibodies and Clinical Associations in a British Cohort with Limited Cutaneous Systemic Sclerosis

REFERENCES

1. 1.↵
   1. Steen VD

   . Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35–42.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. LeRoy EC,
   2. Black C,
   3. Fleischmajer R,
   4. Jablonska S,
   5. Krieg T,
   6. Medsger TA Jr.,
   7. et al.

   Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;31:202–5.

   OpenUrl
3. 3.↵
   1. Gliddon AE,
   2. Doré CJ,
   3. Black CM,
   4. McHugh N,
   5. Moots R,
   6. Denton CP,
   7. et al.

   Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: A multicentre randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007;56:3837–46.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Betteridge Z,
   2. Gunawardena H,
   3. North J,
   4. Slinn J,
   5. McHugh N

   . Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007;56:3132–7.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Spencer-Green G,
   2. Alter D,
   3. Welch HG

   . Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med 1997;103:242–8.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Kuwana M,
   2. Kaburaki J,
   3. Okano Y,
   4. Tojo T,
   5. Homma M

   . Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994;37:75–83.

   OpenUrlPubMed
7. 7.↵
   1. Walker UA,
   2. Tyndall A,
   3. Czirjak L,
   4. Denton C,
   5. Farge-Bancel D,
   6. Kowal-Bielecka O,
   7. et al.

   Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group database. Ann Rheum Dis 2007;66:754–63.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Walker JG,
   2. Fritzler MJ

   . Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007;19:80–91.

   OpenUrl
9. 9.↵
   1. Hesselstrand R,
   2. Scheja A,
   3. Shen GQ,
   4. Wiik A,
   5. Akesson A

   . The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 2003;42:534–40.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Steen VD,
    2. Graham G,
    3. Conte C,
    4. Owens G,
    5. Medsger TA Jr.

    . Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992;35:765–70.

    OpenUrlPubMed
11. 11.↵
    1. Steen V,
    2. Medsger TA Jr.

    . Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516–22.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Ceribelli A,
    2. Cavazzana I,
    3. Franceschini F,
    4. Airo P,
    5. Tincani A,
    6. Cattaneo R,
    7. et al.

    Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 2010;37:2071–5.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Mitri GM,
    2. Lucas M,
    3. Fertig N,
    4. Steen VD,
    5. Medsger TA Jr.

    . A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003;48:203–9.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Tramposch HD,
    2. Smith CD,
    3. Senecal JL,
    4. Rothfield N

    . A long-term longitudinal study of anticentromere antibodies. Arthitis Rheum 1984;27:121–4.

    OpenUrlPubMed